Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

and technical issues; clinical trials, including the DURATION-2 clinical trial mentioned in this press release, not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; pre-clinical trials not predicting future results; label expansion requests or New Drug Application ("NDA") filings, including the NDA filing for exenatide once weekly, not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA, SYMLIN and/or exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products. These risks also include a potential adverse impact on our financial condition if the steps outlined in this press release to address the change of control provisions in two of our debt agreements are unsuccessful and we are required to repay the amounts outstanding under any of our debt agreements. These and additional risks and uncertainties are described more fully in Amylin's most recent SEC filings including its Annual Report on Form 10-K. Amylin undertakes no duty to update these forward-looking statements.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin will be filing a proxy statement with the Securities and Exchange Commission ("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and securityholders will be able to receive the proxy statement and other re
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... HONG KONG , June 2, 2015 /PRNewswire/ -- China Cord ... "us" and "our"), China,s leading provider ... and stem cell storage services, today announced that the Special ... has appointed Houlihan Lokey ( China ... Steen & Hamilton LLP as its United ...
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. Hoffman Company ... Moenninghoff product line . , Moenninghoff President ... the R.M. Hoffman Company will be representing Moenninghoff in ... this is a strategically important step. We are ... distributor we need to successfully grow our business in ...
(Date:6/1/2015)... YONGIN, South Korea , June 1, ... Green Cross Biotherapeutics Inc. (GCBT) kicked off construction today ... the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million project ... in Canada in the biopharmaceutical ... intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... 1, 2015  Novartis is highlighting data from ... an investigational chimeric antigen receptor (CAR) T cell ... of specific types of hard-to-treat non-Hodgkin lymphoma. Findings ... of Pennsylvania,s Perelman School of Medicine (Penn) in ... B-cell lymphoma (DLBCL) and follicular lymphoma (FL) found ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... Europe Ongoing , , DALLAS, June 10 ... (OTC Bulletin Board: ACCP) , announced ... States Patent and Trademark Office that two US patents relating to ... for the management of mucositis will issue in June as US ...
... Calif., June 10 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Business Officer of BioMarin, will present a company update at the ... 2009 at 8:30 a.m. ET. , , Interested ... via the investor section of the BioMarin website, www.BMRN.com ...
... 10 Delcath Systems, Inc. (Nasdaq: DCTH ), ... (PHP(TM)) System for the treatment of cancers of the liver, ... to sell 869,565 units, each unit consisting of one of ... common shares, for gross proceeds of approximately $3 million, before ...
Cached Biology Technology:Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM) 2Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM) 3BioMarin to Present at the Jefferies Healthcare Conference 2Delcath Enters Agreement to Sell 869,565 Units 2Delcath Enters Agreement to Sell 869,565 Units 3
(Date:5/26/2015)... 26, 2015 Research and ... of the "Saudi Arabia Biometric Systems Market ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems ... is projected to grow at over 22% CAGR ... attributed to the surging demand for better biometric ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... identifies regions of the human genome that regulate gene expression ... number of human diseases, according to researchers at Dukes Institute ... DNA in our bodies is packaged, or tightly structured, said ... of the senior investigators on this study. Our goal was ...
... sliding against joints, ink jets splashing on paperliving ... However important these liquid/solid boundaries may be, conventional ... interfaces in their natural environments. Now, researchers at ... and the University of Minnesota have demonstrated a ...
... According to a study published in Nature by researchers ... the hydrology and chemistry of the Mississippi River, injecting ... discharge during the past 50 years. LSU Professor ... with their colleagues at Yale, tracked changes in the ...
Cached Biology News:Search for the 'on' switches may reveal genetic role in development and disease 2Videos extract mechanical properties of liquid-gel interfaces 2LSU, Yale team study agricultural impact on Mississippi River 2
Values of steady state parameters for enzyme activities are determined....
... Proliferator-Activated Receptor-gamma (PPAR) is a member ... ligand-activated transcription factors that heterodimerize with ... involved in the regulation of glucose ... (TZD) class of anti-diabetic agents called ...
... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
Biology Products: